Tissue distribution and pharmacokinetics of centchroman: A new nonsteroidal postcoital contraceptive agent and its 7-desmethyl metabolite in female rats after a single oral dose

Drug Metabolism and Disposition

Volumn 24, Issue 2, 1996, Pages 148-155

  Paliwal, J K ^a   Gupta, R C ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

7 NORCENTCHROMAN; CENTCHROMAN; DRUG METABOLITE; POSTCOITUS CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; LIVER; LUNG; NONHUMAN; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SPLEEN; UTERUS;

ADMINISTRATION, ORAL; ANIMALS; CENTCHROMAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRACEPTIVES, POSTCOITAL, SYNTHETIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TISSUE DISTRIBUTION;

EID: 0030029342     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. S. Ray, P. K. Grover, and N. Anand: New synthesis of cis- and trans-3 phenyl-4-[4-(β-pyrolidinoethoxy)phenyl]-7-methoxychromans. Indian J. Chem. 9, 727-728 (1971).
2. S. Ray, P. K. Grover, V. P. Kamboj, B. S. Setty, A. B. Kar, and N. Anand: Antifertility agents. 12. Structure-activity relationship of 3,4-diphenyl-chromenes and chromans. J. Med. Chem. 19, 276-279 (1976).
3. V. P. Kamboj, A. B. Kar, S. Ray, P. K. Grover, and N. Anand: Antifertility activity of 3-4-trans-2,2-dimethyl-3-phenyl-4-[4-(β-pyrolidinoethoxy-)phenyl]-7- methoxychromans. Indian J. Exp. Biol. 9, 103-105 (1971).
4. S. Roy and J. K. Dutta: Nature of estrogenic and anti-estrogenic actions of centchroman on rat uterus. Contraception 13, 597-604 (1976).
5. V. P. Kamboj, B. S. Setty, H. Chandra, S. K. Roy, and A. B. Kar: Biological profile of centchroman - a new post-coital contraceptive. Indian J. Exp. Biol. 15, 1141-1150 (1977).
6. P. K. Mehrotra, J. N. Karkun, and A. B. Kar: Antiestrogenicity of some nonsteroidal compounds. Indian J. Exp. Biol. 12, 133-135 (1974).
7. N. C. Misra, P. K. Nigam, R. Gupta, A. K. Agarwal, and V. P. Kamboj: Centchroman - a non-steroidal anticancer agent for advanced breast cancer. Phase II study. Int. J. Cancer 43, 781-783 (1989).
8. V. P. Kamboj, S. Ray, and B. N. Dhawan: Centchroman. Drugs Today 28, 227-232 (1992).
9. V. M. Labro, M. Creek, J. R. Piggott, Bothell, and S. D. Bain: Methods for reducing bone loss using centchroman derivatives. U.S. Patent 5280040. Zymogenetics, Inc., Seattle, WA.
10. M. M. Singh and V. P. Kamboj: Effect of centchroman on preimplantation embryonic development and tubal transport in truce. Biol. Reprod. 25, 171-180 (1981).
11. S. Nityanand, C. Wati, L. Singh, J. S. Srivastava, and V. P. Kamboj: Clinical evaluation of centchroman: a new oral contraceptive. In "Hormone Antagonists for Fertility Regulation" (C. P. Puri and P. F. A. Van Look, eds.). Indian Society for the Studies on Reproduction and Fertility. Bombay. India, 1988.
12. J. K. Paliwal, R. C. Gupta, P. K. Grover, O. P. Asthana, J. S. Srivastava, and S. Nityanand: High-performance liquid Chromatographic (HPLC) determination of centchroman in human serum and application to single-dose pharmacokinetics. Pharm. Res. 6, 991-993 (1989).
13. J. Lal, O. P. Asthana, S. Nityanand, and R. C. Gupta: Pharmacokinetics of centchroman in healthy female subjects after oral administration. Contraception in press, 1995.
14. S. Ratna, N. Mishra, S. Ray, and S. K. Roy: Centchroman: tissue distribution and excretion profile in albino rats after oral and intravenous administration. J Basic Appl. Biomed. 2, 31-36 (1994).
15. M. Gibaldi and D. Perrier: "Pharmacokinetics" (J. Swarbrick. ed.), 2nd ed. Marcel Decker, Inc., New York.
16. G. W. Peng and W. L. Chiou: Analysis of drugs and other toxic substances in biological samples for pharmacokinetic studies. J. Chromatogr. 531, 3-50 (1990).
17. B. F. H. Drenth, R. T. Ghijsen, and R. A. Dezeeuw: Universal multichannel ultraviolet detection in the purity analysis of 2-ethyl-3-(4-hydroxybenzoyl)indolizine by high-performance liquid chromatography. J Chromatogr. 238, 113-120 (1982).
18. J. C. Miller, S. A. George, and B. G. Willis: Multichannel detection in high-performance liquid chromatography. Science 218, 241-245 (1982).
19. K. Zech, R. Huber, and H. Elgass: On-line screening for drug metabolites by high-performance liquid chromatography with a diode array detector. J. Chromatogr. 282, 161-167 (1983).
20. T. Alfredson and T. Sheehan: Advances in multichannel photodiode-array based LC detection. Am. Lab. 17, 40-54 (1985).
21. T. Alfredson, T. Sheehan, T. Lenert, S. Aamodt, and L. Correia: Determination of compound identity by group type and class using diodearray detection in high-performance liquid chromatography. J. Chromatogr. 385, 213-223 (1987).
22. S. Ratna, S. K. Roy, S. Ray, P. L. Kole, M. Salman, K. P. Madhusudan, K. P. Sircar, and N. Anand: Centchroman: in vitro metabolism by rat liver homogenate. Drug Dev. Res. 7, 173-178 (1986).
23. S. Ratna, N. C. Mishra, S. Ray, and S. K. Roy: Centchroman: tissue distribution and excretion profile in albino rats after oral and intravenous administration. J. Basic Appl. Biomed. 2, 31-36 (1994).
24. J. M. Fromson, S. Pearson, and S. Bramah: The metabolism of tamoxifen (I.C.I. 46,474). Part I. In laboratory animals. Xenobiotica 3, 693-709 (1973).
25. J. M. Fromson, S. Pearson, and S. Bramah: The metabolism of tamoxifen (I.C.I. 46,474). Part II. In female patients. Xenobiotica 3, 711-714 (1973).
26. S. P. Robinson, C. J. Parker, and V. C. Jordan: Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res. Treat. 16 (Suppl.), S9-S17 (1990).
27. C. K. W. Watts, L. C. Murphy, and R. L. Sutherland: Properties of high affinity intracellular binding sites for antiestrogens. In "Estrogen/Antiestrogen Action and Breast Cancer Therapy" (V. C. Jordan, ed.), pp. 93-114. University of Wisconsin Press, Madison, WI, 1986.
28. K. Sudo, F. J. Monsma, and B. S. Katzenellenbogen: Antiestrogen-binding sites distinct from the estrogen receptor: subcellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology 112, 425-434 (1983).
29. M. A. Miller, Y. Y. Sheen, A. Mullick, and B. S. Katzenellenbogen: Antiestrogen binding to estrogen receptors and additional antiestrogen binding sites in human breast cancer cells. In "Estrogen/Antiestrogen Action and Breast Cancer Therapy" (V. C. Jordan, ed.), pp. 127-148. University of Wisconsin Press, Madison, WI, 1986.
30. S. Durrani and N. Anand: A possible basis for structure-function relationship of estrogens. Int. J. Quant. Chem. 20, 71-83 (1981).
31. M. Salman, S. Ray, A. K. Agarwal, S. Durrani, B. S. Setty, V. P. Kamboj, and N. Anand: Antifertility agents 38: effect of the side chain and its position on its activity of 3,4-diarylchromans. J. Med. Chem. 26, 592-595 (1983).
32. W. K. Morishige and C. A. Uetake: Receptors for androgen and estrogen in rat lung. Endocrinology 102, 1827-1837 (1978).
33. 14C-labeled tamoxifen in spayed female mice. Acta Pharmacol. Toxicol. 50, 171-180 (1981).
34. V. C. Jordan: Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res. Treat. 2, 123-138 (1982).
35. 3H]monohydroxy tamoxifen by immature rat tissue in vivo. Endocrinology 110, 1281-1291 (1982).
36. E. Coezy, J. L. Borgna, and H. Rochefort. Tamoxifen and metabolite in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42, 317-323 (1982).
37. L. Kangas: Introduction to toremifene. Breast Cancer Res. Treat. 16 (Suppl.), S3-S7 (1990).
38. J. L. Borgna and H. Rochefort: Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256, 859-868 (1981).
39. M. Rowland: Physiologic pharmacokinetic model for interanimal species scaling. Pharmacol. Ther. 29, 49-69 (1985).